Dr. Matthew D. Dunn, MD

Dr. Dunn practices at Peter Morton UCLA Medical Building in Los Angeles, California.

Dr. Dunn's NPI, 1639104326, was assigned on July 11, 2006. Dr. Dunn graduated from Keck School of Medicine of USC in 1992. Dr. Dunn's California license number on file is G78638.

Dr. Dunn's primary practice is Peter Morton UCLA Medical Building, at 200 Medical Plz, Los Angeles, CA 90024 in Los Angeles County. The practice phone is (310) 794-9206.

Dr. Dunn's primary practice is Peter Morton UCLA Medical Building in Los Angeles, California. Dr. Dunn is also affiliated with Ronald Reagan UCLA Medical Center. The medical group on file is UCLA Urology. Dmand AI also links Dr. Dunn to 2 more hospitals and 1 group practice or clinic, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Dunn practices, 4 sites in all. Vendor and product names are available with a free account.

Urology is Dr. Dunn's primary specialty in the NPI Registry, under taxonomy code 208800000X. Dr. Dunn is board certified in urology by the American Board of Urology. Dr. Dunn has a license on file in California.

Dmand AI lists bladder disease, enlarged prostate, enlarged prostate transurethral surgery (TURP), erectile dysfunction, kidney cysts, kidney removal surgery, kidney stone disease and prostate cancer among the conditions Dr. Dunn treats.

CMS data shows 1,341 Medicare services from Dr. Dunn across 15 procedure codes in 2024, for 552 Medicare patients. Medicare paid $191,420 for them.

CMS counts 552 Medicare patients who saw Dr. Dunn in 2024. The largest group is 65 to 74, with 231 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 19% are also on Medicaid. Their average risk score is 1.72, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Dunn's median patient age at 69, with 33% women.

In 2024, Dr. Dunn wrote 758 Medicare Part D claims for 273 patients. 92% of them were for generic drugs. CMS names the drug for 648 of them, across 16 drugs with 11 or more claims each, at $139,051 in total drug cost. In 2023, CMS named 742 claims across 18 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 89 out of 100 for Dr. Dunn for performance year 2024, reported as part of a group. Dr. Dunn accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Dunn as offering telehealth. CMS counts 44 procedures of prostate resection by Dr. Dunn, more than 96% of the clinicians it reports for that procedure.

Dmand AI links 21 papers to Dr. Dunn, published from 2007 to 2010. 2010 was the busiest year, with 2. The most frequent topics are Laparoscopy, Nephrectomy and Carcinoma, Transitional Cell. Dr. Dunn has published most often in J Urol. Dr. Dunn's most frequent co-authors are Ralph V. Clayman, MD, Elspeth M. Mcdougall, MD and J Stuart Wolf, MD.

Dmand AI links Dr. Dunn to 1 clinical trial. Conditions studied include Kidney Calculi and Urinary Calculi.

CMS Open Payments shows 203 general payments to Dr. Dunn from 22 drug and device companies from 2016 to 2025. Speaker and faculty fees make up the largest share, 39% of the total. Boston Scientific Corporation paid the most, $38,969.

Dmand AI lists 1 award for Dr. Dunn.

Dr. Dunn graduated from Keck School of Medicine of USC in 1992.

Dr. Dunn is in network with 15 carriers, including Aetna, Elevance and United Healthcare. Medicare plans come from the most carriers, 9. Check the plan with the practice before a visit.